LM
VTGN icon

Luminus Management’s VistaGen Therapeutics VTGN Stock Holding History

Luminus Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.1K Buy
403,115
+7,062
+2% +$4.26K 0.06% 29
2026
Q1 		$226K Buy
396,053
+46,053
+13% +$28K 0.14% 22
2025
Q4 		$232K Buy
+350,000
New +$1.26M 0.2% 20

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Luminus Management's VTGN Position: Q2 2026 in Review

Luminus Management increased its VistaGen Therapeutics (VTGN) stake by 1.8% in Q2 2026, buying an estimated $4.26K and bringing the position to 403,115 shares worth $91.1K. The position accounts for 0.06% of the portfolio, ranked #29.

Luminus Management first reported a position in VTGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $232K in Q4 2025. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Luminus Management held 403,115 shares of VistaGen Therapeutics worth $91.1K as of Q2 2026.
  • Luminus Management bought 7,062 VistaGen Therapeutics shares in Q2 2026, an estimated $4.26K.
  • VistaGen Therapeutics made up 0.06% of Luminus Management's portfolio in Q2 2026, its #29 holding.
  • Luminus Management first reported a position in VistaGen Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Luminus Management's VistaGen Therapeutics position peaked at $232K in Q4 2025.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Luminus Management's 13F filing for Q2 2026, filed 14 Aug 2026.